Please use this identifier to cite or link to this item:
Title: Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis
Author: Turco, Laura
Villanueva, Candid
Mura, Vincenzo La
García Pagán, Juan Carlos
Reiberger, Thomas
Genescà, Joan
Groszmann, Roberto J.
Sharma, Barjesh C.
Merkel, Carlo
Bureau, Christophe
Alvarado Tapias, Edilmar
González-Abraldes Iglesias, Juan
Albillos, Agustín
Bañares, Rafael
Peck-Radosavljevic, Markus
Augustin, Salvador
Sarin, Shiv K.
Bosch, Jaime
García-Tsao, Guadalupe
Keywords: Cirrosi hepàtica
Hipertensió portal
Hepatic cirrhosis
Portal hypertension
Issue Date: 1-Jan-2020
Publisher: Elsevier
Abstract: Background & Aims: In unselected patients with cirrhosis, those with reductions in hepatic venous pressure gradient (HVPG) to below a defined threshold (responders) have a reduced risk of variceal hemorrhage (VH) and death. We performed a meta-analysis to compare this effect in patients with vs without ascites. Methods: We collected data from 15 studies of primary or secondary prophylaxis of VH that reported data on VH and death in responders vs nonresponders. We included studies in which data on ascites at baseline and on other relevant outcomes during follow-up evaluation were available. We performed separate meta-analyses for patients with vs without ascites. Results: Of the 1113 patients included in the studies, 968 patients (87%) had been treated with nonselective β-blockers. In 993 patients (89%), HVPG response was defined as a decrease of more than 20% from baseline (>10% in 11% of patients) or to less than 12 mm Hg. In the 661 patients without ascites, responders (n = 329; 50%) had significantly lower odds of events (ascites, VH, or encephalopathy) than nonresponders (odds ratio [OR], 0.35; 95% CI, 0.22–0.56). Odds of death or liver transplantation were also significantly lower among responders than nonresponders (OR, 0.50, 95% CI, 0.32–0.78). In the 452 patients with ascites, responders (n = 188; 42%) had significantly lower odds of events (VH, refractory ascites, spontaneous bacterial peritonitis, or hepatorenal syndrome) than nonresponders (OR, 0.27; 95% CI, 0.16–0.43). Overall, odds of death or liver transplantation were lower among responders (OR, 0.47; 95% CI, 0.29–0.75). No heterogeneity was observed among studies. Conclusions: In a meta-analysis of clinical trials, we found that patients with cirrhosis with and without ascites who respond to treatment with nonselective β-blockers (based on reductions in HVPG) have a reduced risk of events, death, or liver transplantation.
Note: Versió postprint del document publicat a:
It is part of: Clinical Gastroenterology and Hepatology, 2020, vol. 18, num. 2, p. 313-327.e6
Related resource:
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.